Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intrathecal methotrexate versus central nervous system leukemia.

W A Bleyer

    Cancer Drug Delivery
    |January 1, 1984
    PubMed
    Summary

    Intrathecal methotrexate (IT MTX) is crucial for preventing and treating central nervous system (CNS) leukemia in children with acute lymphoblastic leukemia (ALL). Understanding IT MTX pharmacokinetics and dosage is vital for effective treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The management of cancer in the older adolescent.

    European journal of cancer (Oxford, England : 1990)·2003
    Same author

    Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

    Neuro-oncology·2001
    Same author

    Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

    Leukemia·2001
    Same author

    Oral cancer chemotherapy in paediatric patients: obstacles and potential for development and utilisation.

    Drugs·2000
    Same author

    Epidemiologic impact of children with brain tumors.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·1999
    Same author

    Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.

    Clinical cancer research : an official journal of the American Association for Cancer Research·1999

    Area of Science:

    • Pediatric Oncology
    • Pharmacology
    • Hematology

    Background:

    • Central nervous system (CNS) leukemia is a serious complication in acute lymphoblastic leukemia (ALL).
    • Intrathecal methotrexate (IT MTX) is a primary treatment to prevent or manage CNS leukemia.
    • Understanding the disease and treatment pharmacodynamics is essential.

    Purpose of the Study:

    • To review the pathophysiology of CNS leukemia.
    • To examine clinical aspects influencing IT MTX therapy.
    • To present IT MTX pharmacokinetics and dosage regimen importance.

    Main Methods:

    • Literature review of studies on pediatric ALL patients receiving IT MTX.
    • Analysis of CNS leukemia pathophysiology and clinical manifestations.
    • Pharmacokinetic evaluation of IT MTX.

    Main Results:

    • The review covers CNS leukemia's pathophysiology and clinical factors affecting IT MTX.
    • Pharmacokinetics of IT MTX are detailed.
    • Dosage regimen significance is highlighted.

    Conclusions:

    • Effective IT MTX therapy requires understanding CNS leukemia's complexities.
    • Pharmacokinetic data and appropriate dosage are critical for successful outcomes.
    • This review emphasizes the importance of optimized IT MTX treatment strategies.

    Related Experiment Videos